Here's the last portion of Dr. Socinski's presentation, which covers two important trials in small cell lung cancer (SCLC) presented at ASCO 2012.  The first was a SWOG trial of the standard second line agent topotecan (here given on a weekly schedule) either alone or combined with the antiangiogenic agent Eylea (aflibercept).  The results of this trial were generally considered encouraging enough to warrant further study, and you can learn the details from his talk.

He also covers an important study done by the Japanese Cooperative Oncology Group (JCOG), which compared cisplatin/amrubicin to cisplatin/irinotecan, which is standard first line therapy for extensive stage SCLC in Japan.  Dr. Socinski reviews the results and places them in context for us.

Below is the video and audio versions of the podcast, along with the transcript and figures.

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Transcript

Dr. Socinski ASCO LC Highlights 2012 SCLC Update Figs

We'll have Dr. Joel Neal's coverage of several novel agents for lung cancer that showed promise at ASCO 2012 in the next series of podcasts. Look for those soon.